Solid Biosciences Inc. (NASDAQ: SLDB) Near the Top of Equities by Percentage Gain on 11/15Solid Biosciences Inc. (
NASDAQSLDB) is one of today’s top gainers. The company’s shares have moved 10.58% on the day to $2.09.
Are Gene Therapy Stocks The Market's Next Big Winners?Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio, Inc. pursuant to which shareholders of AavantiBio are expected to own approximately 15% of the combined company, subject to certain adjustments. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
SOLID BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Solid Biosciences Inc. - SLDB
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Solid Biosciences Inc. (“the Company”) (NasdaqGS: SLDB) with AavantiBio, Inc. pursuant to which shareholders of AavantiBio are expected to own approximately 15% of the combined company, subject to certain adjustments. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
SLDB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Solid Biosciences Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Solid Biosciences Inc. (
NASDAQSLDB) and AavantiBio, Inc. is fair to Solid shareholders.
Solid Biosciences and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
Solid Biosciences Inc. (Solid, Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), and Forge Biologics, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), announced a partnership to advance the development and manufacturing of SGT-003, Solid’s next generation gene therapy program for Duchenne. SGT-003 is a preclinical candidate that combines a next-generation and rationally designed capsid with Solid’s proprietary nNOS-containing microdystrophin and has demonstrated enhanced muscle tropism and microdystrophin expression compared to AAV9 in vivo.
